Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes

Contraception

Volumn 75, Issue 2, 2007, Pages 101-107

  Mona Eng, Patricia ^a   Seeger, John D ^a,b   Loughlin, Jeanne ^a   Oh, Kelly ^a   Walker, Alexander M ^a,b  

^a i3 Drug Safety   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Compliance; Oral contraceptives; Physician survey; Potassium monitoring

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROSPIRENONE PLUS ETHINYLESTRADIOL; HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT;

ARTICLE; BLOOD EXAMINATION; CONTROLLED STUDY; FEMALE; HEALTH CARE PLANNING; HEALTH SURVEY; HUMAN; HUMAN EXPERIMENT; HYPERKALEMIA; MEDICAL SERVICE; ORAL CONTRACEPTION; PATIENT COMPLIANCE; PATIENT MONITORING; PHYSICIAN; PHYSICIAN ATTITUDE; POTASSIUM BLOOD LEVEL; PRESCRIPTION; PROFESSIONAL KNOWLEDGE; REIMBURSEMENT; TELEPHONE;

ADOLESCENT; ADULT; ANDROSTENES; CASE-CONTROL STUDIES; CHILD; CONTRACEPTIVES, ORAL, COMBINED; DRUG MONITORING; DRUG UTILIZATION; ETHINYL ESTRADIOL; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERKALEMIA; INSURANCE CLAIM REVIEW; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; POTASSIUM; PROGESTERONE CONGENERS; UNITED STATES;

EID: 33846221141     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2006.08.011     Document Type: Article

References (11)

1. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
2. Shah K.B., Krishnamurti R., Sawyer R., and Gottleib S.S. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 46 (2005) 845-849
3. Raebel M.A., Lyons E.A., Andrade S.E., et al. Laboratory monitoring of drugs at initiation of therapy in ambulatory care. J Gen Intern Med 20 (2005) 1120-1126
4. Hurley J.S., Roberts M., Solberg L.I., et al. Brief report: laboratory safety monitoring of chronic medications in ambulatory care settings. J Gen Intern Med 20 (2005) 331-333
5. Raebel MA, McClure DL, Simon SR, et al. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Safety [Published online Feb 8, 2006].
6. Walker A.M., Bortnichak E.A., Lanza L., and Yood R.A. The infrequency of liver function testing in patients using nonsteroidal anti-inflammatory drugs. Arch Fam Med 4 (1995) 24-29
7. Wagner A.K., Chan K.A., Dashevsky I., et al. FDA drug prescribing warnings: is the black box half empty of half full?. Pharmacoepidemiol Drug Safety 15 (2006) 369-386
8. Graham D.J., Drinkard C.R., Shatin D., Tsong Y.I., and Burgess M.J. Liver enzyme monitoring in patients treated with troglitazone. JAMA 286 (2001) 831-833
9. Weatherby L.B., Walker A.M., Fife D., Vervaet P., and Klausner M.A. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear Doctor' letters. Pharmacoepidemiol Drug Saf 10 (2001) 211-218
10. Preston R.A., William W.B., Pitt B., Bakris G., Norris P.M., and Hanes V. Effects of drospirenone/17-β estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 18 (2005) 797-804
11. Loughlin J, Seeger JD, Eng PM, Clifford RC, Cutone J, Walker AM. Risk of hyperkalemia in women taking ethinyl estradiol/drospirenone and other oral contraceptives [submitted for publication].